NASDAQ:KYMR - Kymera Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $48.67
  • Forecasted Upside: 25.88 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$38.66
▲ +0.1 (0.26%)
1 month | 3 months | 12 months
Get New Kymera Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KYMR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KYMR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$48.67
▲ +25.88% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $48.67, with a high forecast of $69.00 and a low forecast of $35.00. The average price target represents a 25.88% upside from the last price of $38.66.
Buy
The current consensus among 7 investment analysts is to buy stock in Kymera Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/14/2021Berenberg BankInitiated CoverageBuyHigh
i
3/29/2021Morgan StanleyLower Price TargetEqual Weight$74.00 ➝ $69.00N/A
i
3/23/2021Morgan StanleyLower Price TargetEqual Weight$74.00 ➝ $69.00High
i
1/19/2021Morgan StanleyBoost Price TargetEqual Weight$45.00 ➝ $74.00High
i
12/4/2020HC WainwrightInitiated CoverageBuyMedium
i
Rating by A. Fein at HC Wainwright
11/24/2020Morgan StanleyBoost Price TargetEqual Weight$27.00 ➝ $45.00High
i
11/13/2020Piper SandlerInitiated CoverageOverweightLow
i
9/15/2020Bank of AmericaInitiated CoverageNeutral$35.00High
i
9/15/2020Morgan StanleyInitiated CoverageEqual Weight$27.00High
i
9/15/2020GuggenheimInitiated CoverageBuy$42.00High
i
9/15/2020CowenInitiated CoverageOutperformHigh
i
(Data available from 4/18/2016 forward)
Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $38.66
$37.07
$38.79

50 Day Range

MA: $44.12
$31.08
$60.04

52 Week Range

Now: $38.66
$25.43
$91.92

Volume

482,865 shs

Average Volume

326,153 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Kymera Therapeutics?

The following Wall Street research analysts have issued stock ratings on Kymera Therapeutics in the last twelve months: Bank of America Co., Berenberg Bank, Cowen Inc, Guggenheim, HC Wainwright, Morgan Stanley, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for KYMR.

What is the current price target for Kymera Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Kymera Therapeutics in the last year. Their average twelve-month price target is $48.67, suggesting a possible upside of 25.9%. Morgan Stanley has the highest price target set, predicting KYMR will reach $69.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $35.00 for Kymera Therapeutics in the next year.
View the latest price targets for KYMR.

What is the current consensus analyst rating for Kymera Therapeutics?

Kymera Therapeutics currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KYMR will outperform the market and that investors should add to their positions of Kymera Therapeutics.
View the latest ratings for KYMR.

What other companies compete with Kymera Therapeutics?

How do I contact Kymera Therapeutics' investor relations team?

Kymera Therapeutics' physical mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The company's listed phone number is 857-285-5300 and its investor relations email address is [email protected] The official website for Kymera Therapeutics is www.kymeratx.com.